Verrufilm

Quick links

Choose a section

Quick links to important sections

Advertisements

Verrufilm

Advertisements
Advertisements

Method of action: Emollients And Protectives

Treatment option: Warts

Advertisements

Overview of Verrufilm

Property Description
Active Ingredients Lactic Acid, Sodium Salicylate
Form Topical Solution (Collodion)
Pharmacological Class Keratolytic, Coricide
General Purpose Managing Hyperkeratotic Skin Lesions
Origin Combination of Synthetic Hydroxy Acids

What Type of Medicine is Verrufilm?

Verrufilm is a non-prescription medicinal preparation classified pharmacologically as a keratolytic agent, intended strictly for topical use on the skin's outer layer. This specific combination is widely clinically recognized for its efficacy in treating highly localized areas of pronounced skin thickening, a condition medically known as hyperkeratosis. As a dual-compound formula, it contains Salicylic Acid (in the form of Sodium Salicylate) and Lactic Acid, placing it within the group of combined topical Salicylates known for their ability to promote desquamation and softening tissue.

What is Verrufilm Made of and What is its Form?

The product is a combination product containing the two primary Hydroxy Acids: Lactic Acid and Sodium Salicylate. This preparation is delivered as a thin, clear topical solution formulated in a specialized collodion base for external use. This solvent allows the liquid to dry rapidly on the skin, forming an adherent film that ensures the concentrated and prolonged contact of the active ingredients with the targeted area. This film-forming property makes the preparation distinct, as it is designed for localized delivery, reducing runoff from the application site and assisting the dissolution of hyperkeratotic scales.

How Does its Keratolytic Action Benefit the Skin?

The core mechanism of Verrufilm is its powerful keratolytic action, which is the chemical process of softening and dissolving keratin, the main structural protein in the hardened outer skin layer. This dual-acid action promotes the targeted breakdown and separation of excess, toughened skin cells from the healthy underlying tissue. The general benefit is the ability to achieve the controlled, progressive sloughing of the affected skin mass, assisting in normalizing the skin's surface and reducing the thickness of the lesion.

Regulatory References

  1. Salicylates Reference
Advertisements

What side effects are possible with Verrufilm?

Possible Side Effects and Safety Information

The official safety profile for topical Lactic Acid and Sodium Salicylate solutions, such as Verrufilm, is primarily defined by localized adverse reactions and specific population-based safety constraints documented in regulatory sources.

Frequency-Classified Adverse Reactions

The most commonly reported effects are local, affecting the application site, and are generally classified as very common or common in official labeling. The risks are typically grouped by the affected System-Organ Class (SOC).

SOC Category Classification Example Adverse Reactions (as listed)
Skin and subcutaneous tissue disorders Very Common Burning sensation, pruritus, erythema, scaling, dryness, application site reaction.
Skin and subcutaneous tissue disorders Common Rash, skin hypertrophy (thickening).
Immune system disorders Rare Application site hypersensitivity, including inflammation.
Systemic Risk Not Known Salicylate toxicity (salicylism) symptoms, linked to excessive systemic absorption.

Serious Adverse Reactions and Systemic Risk

While local effects are common, the most serious documented risk is Salicylate Toxicity (Salicylism), which is associated with prolonged, excessive, or large-area application. The potential for Reye’s syndrome is a specific constraint listed for children and teenagers with concomitant viral illness (e.g., influenza or chickenpox) due to the systemic absorption of salicylates.

Population-Specific Safety Considerations

The medicine is contraindicated in patients with diabetes mellitus or impaired peripheral blood circulation due to the increased risk of severe local skin damage. Use is generally not recommended during pregnancy or lactation, or in children under 2 years of age. Patients with underlying kidney or liver disease may have an increased risk of toxicity if the product is used for an extended duration over large body surface areas.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose scenarios related primarily to accidental oral ingestion of the solution or excessive topical use resulting in systemic absorption of Salicylic Acid.

Overdose may present as systemic salicylate toxicity (salicylism), which is a serious condition. Documented manifestations of salicylism include tinnitus (ringing in the ears), hearing loss, confusion, headache, rapid breathing, and gastrointestinal effects such as nausea and vomiting. Severe localized injury, including chemical burns or ulceration, is also documented as a risk of misuse or excessive topical application.

Emergency Actions and Urgent Medical Attention

Immediate medical attention must be sought for accidental oral ingestion or if any severe systemic symptoms develop. This action is mandated by official regulatory documents. In cases of accidental oral ingestion, treatment steps described in official labeling may include gastric lavage and monitoring of fluid and electrolyte balance. No specific antidote is known for this overdose.

Population-Specific Risk

Official sources note a specific risk in the pediatric population: children and teenagers should not use products containing salicylate during or immediately after a viral illness due to the potential for developing Reye's syndrome, a severe, life-threatening condition.

Advertisements

Therapeutic Uses of Verrufilm

The keratolytic preparation is commonly used in the specialized therapeutic domain of managing focal skin lesions characterized by pronounced thickening and hardness. The use of this class of topical agents is applied in conditions involving the overgrowth or scaling of skin cells, helping to soften and loosen the thickened tissue so it may be progressively separated. The primary focus of this treatment is the localized management of certain growths and hyperkeratotic lesions.

This solution is relevant in common conditions, including common warts (verruca vulgaris), verrucas (plantar warts), and hard corns and calluses. The topical application helps address the symptoms of the lesion's rough, elevated surface and hardened epidermal mass.

“By addressing the pronounced thickness and hardened skin mass, this management approach supports the reduction of the lesion’s size.”

The overall benefit is the assistance in restoring the skin’s normal, smooth surface after the progressive separation of the abnormal growth. This contributes to improved comfort by helping to ease the pressure-induced discomfort and localized tenderness often associated with these chronic, thickened skin areas.


Quick Fact: Relief for Pressure-Induced Discomfort The reduction of the hyperkeratotic mass may assist with maintaining functional stability, particularly in lesions located on the soles of the feet.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Verrufilm?

Verrufilm's official eligibility profile is strictly defined by regulatory documents, primarily based on patient health conditions, age, and application site integrity.

Contraindicated and Restricted Populations

Population Group Eligibility Status (Regulatory Labeling)
Children under 2 years Contraindicated
Diabetes Mellitus Contraindicated
Poor Peripheral Circulation Contraindicated
Known Hypersensitivity Contraindicated
Pregnancy/Lactation Not Recommended (Conditional Use)
Irritated/Infected Skin Contraindicated (Application Site)
Face, Moles, Birthmarks Contraindicated (Application Site)

The solution is absolutely contraindicated for patients diagnosed with diabetes mellitus or any condition resulting in impaired peripheral circulation, due to the heightened risk of localized tissue damage and poor healing. Use is also strictly prohibited on children under two years of age and in individuals with a known allergy or hypersensitivity to Salicylic Acid or Lactic Acid.

For eligible populations, including adults and children aged two years and older, use is conditional: the application must be restricted to a small area and must not be applied to the face, moles, birthmarks, or any infected, irritated, or inflamed skin. Use during pregnancy and lactation is generally not recommended by regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

Documented Pharmacodynamic and Topical Interactions

The official prescribing information restricts the co-administration of Verrufilm with other topical keratolytic or peeling agents. This constraint is due to a documented pharmacodynamic interaction which can result in an additive local effect, potentially leading to excessive local irritation or pronounced desquamation of the skin. This effect requires the avoidance of simultaneous application of any other topical treatments to the same localized area.

Systemic Exposure and Pharmacokinetic Risk

The product's interaction profile notes precautions concerning systemic exposure, which are dependent on application conditions. A pharmacokinetic interaction risk exists where the systemic concentration of Salicylate may be increased if the product is applied to large surface areas or used under occlusive (airtight) dressings. This potential for enhanced systemic Salicylate exposure requires official regulatory caution for individuals concurrently receiving oral anticoagulant medications. This includes specific medicines such as Warfarin, where the theoretical increase in systemic Salicylate levels could potentiate the anticoagulant effect. No systemic drug–drug interactions involving metabolic enzymes (CYP) or transporters are documented in the regulatory prescribing information for this localized topical solution.

Advertisements

Mechanism of Action

How Verrufilm Works: Mechanism of Action

Chemical Softening and Keratin Breakdown

The drug's mechanism initiates with a chemical denaturant action that targets the keratin protein and the desmosomal junctions responsible for cell-to-cell adhesion in the outer epithelial layer. This interaction leads to the softening and structural breakdown of the tough tissue, a key physiological consequence that facilitates the progression of the chemical debridement.


Targeted Epidermal Cell Lysis and Debridement

This domain describes the drug's cytolytic activity, which chemically destroys and dissolves the targeted epidermal cells layer by layer. By interfering with cellular structure, the drug induces a process of controlled erosion and tissue shedding. The resulting physiological effect is the progressive, targeted removal of the localized tissue, which defines the drug's characteristic physiological effect of tissue erosion.


Localized Physiological Signal Induction

The application of the drug initiates a localized chemical irritation that acts as a physiological signal to the surrounding tissue. This signal may recruit certain cells associated with the body’s natural immune and repair mechanisms. The resulting physiological effect facilitates the localized separation and progressive removal of the targeted layers and is consistent with the body's localized physiological response during tissue separation and remodeling.

Advertisements

Dosage and Administration Information

How Verrufilm is Used

Verrufilm is administered as a topical solution strictly for external use, applying the preparation directly onto the localized hyperkeratotic lesion. This combination of Lactic Acid and Salicylic Acid is typically prepared as a collodion-based solution, often with a concentration of 16.7% for each acid.


Official Dosing and Administration Protocol

The standard protocol mandates application once daily, preferably scheduled for use in the evening at bedtime to ensure the film adheres for a prolonged period. The treatment duration is guided by lesion clearance, continuing until the normal skin architecture is restored, generally taking approximately 8 weeks, with a maximum duration of up to 12 weeks.


Required Procedural Steps

Prior to each application, the affected area must be soaked in warm water for approximately five minutes and thoroughly dried. The solution is applied using the provided applicator to deliver a thin layer or one to two drops, strictly covering only the lesion while avoiding the surrounding healthy skin. The solution must then be allowed to dry thoroughly. To assist the removal of the hardened tissue, the surface of the lesion should be gently abraded every two to three days using an appropriate tool, such as a pumice stone. Treatment should be temporarily suspended for two to three days if bleeding occurs following abrasion.


Age-Specific Use Constraints

There are specific constraints for pediatric use. Treatment for children under the age of 12 years requires supervision during application. The product is generally not recommended for infants under the age of two years.

Advertisements

Recent Clinical Evidence

This overview summarizes the structure of the clinical research supporting the use of the active ingredients in Verrufilm (topical Salicylic Acid and Lactic Acid), focusing on the types of studies that exist, the outcomes they examined, and the limitations noted in the evidence base. This information is derived from systematic reviews and governmental sources.


Evidence for Warts (Verruca Vulgaris and Plantar Warts)

The primary evidence for these conditions relies on Randomized Controlled Trials (RCTs), with findings consolidated through systematic reviews and meta-analyses. Researchers examined patient groups including adults and older children, with the central clinical measure focusing on complete lesion clearance. Studies also examined measurements against non-active controls (placebo) and other localized treatments. Findings describe patterns observed in these studies, with endpoints typically reported after a 12 to 13-week treatment period.

Evidence for Hard Corns and Calluses

Research has explored the use of these acids for localized skin thickening, such as corns and calluses, using RCTs and observational studies. Studies monitored outcomes related to physical discomfort and the physical removal of the hyperkeratotic mass. Reported patterns were observed in studies that included other physical removal methods, with outcomes typically reported over short-term durations, often up to 14 days of active use.

Research Gaps and Limitations

The full picture of long-term outcomes following treatment, such as the probability of recurrence, is not consistently or fully established; follow-up durations were limited. Evidence quality varies across studies, and findings were mixed when the topical acid solution was studied alongside certain other localized treatments. Furthermore, data for special populations remain insufficient, particularly for very young children (typically under two years) and older adults with co-existing medical conditions.

Key Studies & References Salicylic Acid Topical Drug Information (NIH MedlinePlus)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Verrufilm (FAQ)


Q: What happens if Verrufilm gets on healthy skin?

Official product information advises strictly applying the solution only to the localized lesion, avoiding contact with healthy, surrounding skin. This caution is necessary because the active ingredients are keratolytic, designed to affect skin tissue. If the solution accidentally gets onto healthy skin, regulatory guidance recommends washing the area off immediately and thoroughly with water.


Q: Can I apply makeup or lotion over Verrufilm?

Regulatory guidance for these types of topical treatments often advises cleansing the application area beforehand to remove any cosmetics or lotions. While product labels do not specifically address applying makeup or lotion over the dried film, regulatory advice often focuses on avoiding the use of other topical agents at the same site, as this interaction is not consistently studied.


Q: Can Verrufilm be used on corns or calluses?

Official product information in some regions indicates that this preparation, due to its keratolytic action (softening of keratin), is supported for use on foot corns and hard calluses, in addition to warts. The drug's mechanism is designed to progressively remove localized areas of pronounced skin thickening.


Q: What should I do if I experience a burning sensation after applying Verrufilm?

A burning sensation at the application site is listed as a very common side effect in the official safety profile, and this is generally expected with keratolytic agents. If the discomfort becomes severe, or if the application causes bleeding, regulatory guidance indicates that treatment may need to be temporarily suspended for two to three days.


Q: What happens if the wart doesn't respond to Verrufilm treatment?

Official administration protocols specify that the full course of treatment usually continues for approximately 8 weeks, up to a maximum duration of 12 weeks. If the lesion has not cleared or if symptoms persist after using the medicine for the maximum permitted duration, product documentation suggests that consultation with a healthcare professional may be necessary.


Q: What should I do if I accidentally swallow Verrufilm?

The solution is strictly for external, topical use. Accidental ingestion carries a risk of systemic exposure to salicylates. If this occurs, consultation with a local poison control center or emergency medical services is necessary for immediate guidance.


Q: Is Verrufilm different from other common over-the-counter wart treatments?

Verrufilm is officially classified as a non-prescription keratolytic medicine, which means it works by chemically breaking down hard skin tissue. It is a combination product containing two active hydroxy acids (Salicylic Acid and Lactic Acid) formulated in a collodion base, which helps the solution form an adherent film.


Q: Does Verrufilm hurt when applied?

The official safety profile lists a burning sensation as a very common side effect at the application site. Other possible local reactions, such as mild skin irritation and stinging, are also reported. These effects are generally associated with the chemical action of the keratolytic ingredients.


Q: How long does it usually take for Verrufilm to show results?

While the full treatment course may be required for complete clearance (up to 8 to 12 weeks), visible results, such as the softening or peeling of the wart tissue, can begin earlier. This softening facilitates the physical removal of the dead skin layers as part of the overall treatment process.


Q: Is it normal for the skin around the application area to turn white?

A temporary whitish appearance in the treated area is a described, expected effect associated with keratolytic agents. This visual change is generally related to the keratolytic action that causes skin softening and the presence of the dried solution.


Q: What's the difference between Verrufilm and treatments that freeze the wart?

Verrufilm works via a chemical keratolytic action to soften and dissolve the wart tissue. Treatments that freeze the wart, known as cryotherapy, use very cold temperatures to destroy the tissue. The chemical method described is one of the established treatment approaches for warts.


Q: Do I need a prescription to buy Verrufilm?

According to its regulatory classification, Verrufilm is an officially approved non-prescription medicine. It is typically available as an over-the-counter (OTC) product.


Q: How do I know if the wart is fully gone after using Verrufilm?

Official treatment protocols state that the medicine should continue to be used until the wart is no longer visible and the skin at the site appears normal. This is typically confirmed when there are no remaining signs of the wart tissue, such as black dots (capillary remnants) or grainy textured areas.


Q: Does Verrufilm leave a scar?

Studies and general guidance suggest that when used as directed, treatments based on salicylic acid typically do not result in scarring. However, the official safety profile warns against use on irritated or inflamed skin, as this application site is associated with a risk of localized tissue damage.


Q: Can I file the wart down before or during Verrufilm treatment?

Official administration protocols state that the surface of the lesion should be gently abraded (filed down) every two to three days using an appropriate tool, such as a pumice stone or file. This step is intended to help remove the hardened tissue before the next application.


Q: Does Verrufilm work by dissolving or killing the wart tissue?

Verrufilm works through a process called keratolysis. This is a chemical process where the active ingredients soften and dissolve the protein structure (keratin) in the outer layers of the wart tissue. This action results in the progressive, targeted removal of the affected skin mass.

Advertisements

How should Verrufilm be stored and disposed of?

How to Store and Dispose of Verrufilm

This information is based on official regulatory labeling regarding storage, handling, and disposal requirements.

Storage Requirements

Requirement Category Official Instruction
Temperature & Environment Store at ambient temperature, typically not exceeding 25 C or 30 C. Do not refrigerate or freeze.
Container & Handling Keep the bottle/container tightly closed. As the product is highly flammable, protect it from heat, light, sparks, open flames, and hot surfaces.
Stability Do not use the medicine after the expiry date (EXP) stated on the packaging.
Child Safety Always store this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Verrufilm must not be disposed of via household waste or wastewater (flushed down the toilet or poured down the sink). Regulatory guidelines mandate returning the medicine to a pharmacist or a designated pharmaceutical waste collection scheme to ensure proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Verrufilm found in:

A-Z Index: